Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction Alirocumab monotherapy reduced "bad" cholesterol three times more than ezetimibe PARIS and TARRYTOWN, N.Y., Oct. 16, 2013 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that ... (more)
http://www.drugs.com/clinical_trials/sanofi-regeneron-cuts-ldl-phase-iii-study-16197.html?
http://www.drugs.com/clinical_trials/sanofi-regeneron-cuts-ldl-phase-iii-study-16197.html?
No comments:
Post a Comment